Format

Send to

Choose Destination
Curr Opin Immunol. 1998 Oct;10(5):573-80.

Clinical applications of TNF-alpha in cancer.

Author information

1
Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier UniversitaireVaudois (CHUV), Rue du Bugnon 46, CH-1011, Lausanne, Switzerland. Ferdy.Lejeune@chuv.hospvd.ch

Abstract

High-dose TNF-alpha plus chemotherapy, with or without IFN-gamma, can be safely administered regionally through isolated limb perfusion. This procedure produced between 70% and 80% complete remission in cases of in transit melanoma metastases and between 25% and 36% complete remission in cases of inextirpable soft-tissue sarcomas. Dual targeting is involved; TNF-alpha and IFN-gamma induce apoptosis of angiogenic endothelium, while melphalan induces apoptosis of tumour cells.

PMID:
9794839
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center